Our Passion
What unites us at Rentschler Biopharma, is the passion for what we do. As a full-service CDMO we are your outsourcing partner for the bioprocess development, cGMP manufacturing as well as for the elaboration of approval strategies for your products. Thanks to our many years of experience, the quality of our associated consulting activities, and our expertise in finding solutions, we are among the top suppliers in our field.
Founded in 1927, Rentschler is a family owned and independent company. Our company structure guarantees rapid decision-making and efficient, smooth-running processes, and consequently keeping project timelines.
Already in the early beginnings of biotechnology, Rentschler has built up a reputation with the development of different Interferon products (Fiblaferon, Polyferon).
Nowadays, our attention is firmly focused on your products. For the success of your project we can refer to our experience in various molecules like antibodies, fusion proteins or enzymes. Thanks to our focus on innovations, we are always on the cutting edge of technologies.
Our Mission Statement
Our Conviction
We provide an important contribution to biopharmaceuticals, thereby helping millions of people each day. We are among the best in the industry and set new standards in client focus, individual customized solutions and reliability. This is precisely what the Rentschler brand stands for and we are proud of it. Within just a few years, we have become a leading company in our field. This confirms our ability to perform both now and in future.
Client Benefit
We successfully lead projects for our clients, thus ensuring their competitiveness in the markets. We deliver products according to their needs and timelines. Every project with Rentschler Biopharma is in expert hands. For our clients, the Rentschler Biopharma brand stands for expertise in finding solutions, years of experience, innovation, independence, quality of our associated consulting activities and fastest possible time to market. Thus, we minimize the business risk of our demanding global clientele.
Our Business Objective
We make an essential contribution to the global availability of biopharmaceuticals. We generate sufficient earning power and liquidity, which enables us to remain a solid, family owned, medium-sized company and be able to act independently over the long term.
Management

Chief Executive Officer

Chief Financial Officer
Short CV
Short CV
Dr. Frank Mathias studied pharmacy at the Paris VI University where he graduated in the field of immunology in 1991. He has gained more than 25 years’ experience in leading positions in the pharmaceutical and biotech industry. His professional career began when he assumed a position as International Product Manager at Hoechst AG. After that, he became General Manager of the successful and renowned companies Servier Deutschland and Amgen GmbH in Munich. Dr. Frank Mathias was Chief Executive Officer of the Medigene AG from May 2009 until January 2016. He joined the company in 2008 as Chief Operating Officer taken the responsibility for Marketing, Sales and Business Development. In addition, he is Chairman of vfa bio which represents the biotech interests within the German Association of Research-Based Pharmaceutical Companies. Since April 1st, 2016 Dr. Frank Mathias has been Chief Executive Officer of Rentschler Biopharma SE.
Alexander Dettmer studied in Boston, MA, USA as well as in Singapore and holds a Diploma in Economics and Business Administration (Lic. Oec.) from the University of St. Gallen (HSG), Switzerland. Prior to joining Rentschler Biopharma, Mr. Dettmer successfully held several senior leadership positions within the Fresenius SE & Co. KGaA group, which he joined in 2005. His last role was Senior Vice President Corporate Business Development/M&A, where he led the broader M&A team that managed M&A transaction processes. Previous to that, he was CFO of Fresenius Kabi's Medical Devices Division, Executive VP Finance, Procurement & HR, where his responsibilities included financial planning, controlling, compliance, strategic purchasing and product partnering. Before that, he was CFO and Managing Director at Fresenius Biotech GmbH (now: Neovii Biotech).
Facts and Figures
Our company
- Medium-sized, family owned company
- Since founded in 1927, the company is owned by the family Rentschler
- Chairman of the supervisory board is
Prof. Dr. Nikolaus F. Rentschler - Headquarters: Laupheim, Germany
- Site in Milford, MA, USA
- Gross area: more than 40,000 m²
- Biotechnology pioneer
- Full-service contract supplier
- Contract development and manufacturing of biopharmaceuticals in mammalian cell culture
Our clients
- We are the outsourcing partner for more than 100 clients worldwide
- Small, Mid and Big Pharma and Biotech companies have been working with us
- We offer reliable and detailed consulting services
- A significant proportion of our clients relied on us for many years and work together with us on several projects
Our track record
- Expertise with over 200 different molecules
- Over 250 batches in active pharmaceutical ingredient manufacturing
- For about 30 % of our cell culture processes we use continuous mode
- Successful implementation of single-use bioreactors and single-use materials for protein purification
- Constant and continuous expansion of capacity in process development, manufacturing and quality control
Strategic Alliance
Strategic Alliance with Leukocare AG
The Alliance of Rentschler Biopharma and Leukocare offers contract development and manufacturing with proven excellence including best-in-class formulation that enables clients to realize the full medical and commercial potential of their products.
Advanced formulation development is considered at every step of the development and manufacturing process to capitalize on the full product potential.
Leukocare is the specialized technology partner and the exclusive formulation developer for Rentschler Biopharma's biopharmaceuticals business. Rentschler Biopharma is the first and only contract development and manufacturing organization to use Leukocare´s patented SPS® formulation Technology (SPS® = Stabilizing and Protecting Solutions).
Associations
Rentschler Biopharma is a member of the following associations
Quality and Sustainability

Quality is an overall concept of Rentschler Biopharma: Competent consulting in the beginning, followed by the project design up to implementation and reliable production of the drug substance or the drug product. Our manufacturing of active pharmaceutical ingredients in state-of-the-art cGMP facilities meets the highest standards of the biopharmaceutical industry. In order to guarantee this, we have high quality standards on our internal cooperation, on our team. The quality of our performance and results is ensured by comprehensive quality management and precise and reliable quality control. In doing so, we pay attention to continuous monitoring and the adaptation of our quality standards.
Our goal is to enable you to bring to market as quickly as possible a product with the desired therapeutic effect, at the requested level of quality, and in the amount required.
Not only do we make the highest demands on the quality of our work, but also on our relationship with the environment. In our production, we pay attention not only to significantly reducing our quantities of trash but also using the most energy-efficient appliances. We have also operated our own Combined Heat and Power Plant since 2013 on our corporate premises. This facility enables us to produce up to 75 % of our own power supply. Additional diesel emergency generators allow us to be completely self-sufficient, if necessary. This allows us to ensure that manufacturing processes can go on as usual and maintain the quality of our work even during a power blackout. In addition to ensuring security of our power supply, the CHP provides sustainable and environmentally friendly heat and steam for our manufacturing facilities, and as a result, we reduce CO emissions by approximately 2,500 tons annually.
Milestones in Rentschler's History
1927
Foundation as a pharmaceutical manufacturer

Foundation as a pharmaceutical manufacturer
1974
Installation of the biotechnology division

Installation of the biotechnology division
1979
Start working with recombinant cell lines

Start working with recombinant cell lines
1983
World´s first market approval for a natural Interferon-ß (Fiblaferon)

World´s first market approval for a natural Interferon-ß (Fiblaferon)
1989
Approval of a recombinant Interferon-y (Polyferon) and a topical Interferon-ß-gel

Approval of a recombinant Interferon-y (Polyferon) and a topical Interferon-ß-gel
1997
Entering the business of contract development and manufacturing of biopharmaceuticals

Entering the business of contract development and manufacturing of biopharmaceuticals
2006
Foundation of Rentschler Biopharma Inc.

Foundation of Rentschler Biopharma Inc.
2008
Extension of manufacturing facilities (1 x 3,000 L stainless steel, 2 x 1,000 L single-use bioreactors)

Extension of manufacturing facilities (1 x 3,000 L stainless steel, 2 x 1,000 L single-use bioreactors)
2013
Implementing of own Combined Heat and Power plant

Implementing of own Combined Heat and Power plant
2014
First project with the TurboCell™ technology platform

First project with the TurboCell™ technology platform
2015
Manufacturing starts in the first 2,000 L single-use bioreactor

Manufacturing starts in the first 2,000 L single-use bioreactor
2016
Expansion of manufacturing capacity
2x 3,000 L Twin facility, second 2,000 L single-use bioreactor

Expansion of manufacturing capacity
2x 3,000 L Twin facility, second 2,000 L single-use bioreactor
2017
Alliance between Rentschler Biopharma and Leukocare
Rentschler Biopharma will acquire a 10 % stake in Leukocare

Alliance between Rentschler Biopharma and Leukocare
Rentschler Biopharma will acquire a 10 % stake in Leukocare
2019
Acquisition of site in Milford, MA, USA

Acquisition of site in Milford, MA, USA
2020
Strategic collaboration with Vetter

Strategic collaboration with Vetter